Teva Pharmaceutical Industries Limited (TEVA) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Teva Pharmaceutical Industries Limited  (NYSE: TEVA)

Teva Pharmaceutical Industries Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Teva Pharmaceutical Industries Limited in the second quarter 2026?
Teva Pharmaceutical Industries Limited achieved a return on average equity (ROE) of 9.11 % in its second quarter 2026, this is above TEVA's average return on equity of -5.36%.
Teva Pharmaceutical Industries Limiteds equity during the 12 months ending in the second quarter 2026 are valued at $7 billion

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 54 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 584 to 647.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 13.51 % 31.25 % 47.03 % 13.58 % -
Y / Y Net Income Change - 67.73 % - - -
Net Income (TTM) in Millions 709 1,567 1,418 661 -163
Return On Equity (TTM) 9.11 % 20.74 % 20.07 % 10.27 % -2.62 %
TEVA's Total Ranking # 647 # 584 # 116 # 1233 # 2071
Equity (TTM) in Millions 7,757 8,228 7,910 7,250 6,834
Seq. Equity Change -5.72 % 4.02 % 9.1 % 6.09 % 9.01 %
Seq. Net Income Change - -23.28 % 10.83 % 53.36 % 28.64 %

Back to TEVA Management Effectiveness >> TEVA's 5 Years Annual ROE >> Compare TEVA ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 55
Sector # 150
Overall # 647

Return On Equity Statistics
High Average Low
20.74 %
-5.36 %
-66.82 %
(Mar 31 2026)   (Mar 31 2018)





TEVA Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 7,910 5,380 8,126 8,598 11,244
Y / Y Equity Change 47.03 % -33.79 % -5.49 % -23.53 % 1.65 %
Net Income in Millions 1,418 -1,959 -615 -2,499 456
Y / Y Net Income Change - - - - -
Return On Equity 17.93 % -36.41 % -7.57 % -29.06 % 4.06 %

Back to TEVA Management Effectiveness >> TEVA's 5 Years Annual ROE >> Compare TEVA ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 17.93 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TEVA's' Return on Equity at Yahoo Finance
TEVA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TEVA's Competitors
Subscribers only: Roe for Teva Pharmaceutical Industries Limited's Suppliers
Subscribers only: Return On Equity for TEVA's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Resmed Inc   24.21 %
Healthcare Services Group Inc   24.12 %
Electromed Inc   23.65 %
Iradimed Corporation  23.45 %
Vertex Pharmaceuticals Inc  23.31 %
Lantheus Holdings Inc   23.27 %
Msa Safety Inc  23.15 %
Prestige Consumer Healthcare Inc   21.77 %
Jazz Pharmaceuticals Plc  21.37 %
Neurocrine Biosciences Inc   21.13 %
Universal Health Services Inc   20.89 %
Puma Biotechnology Inc   20.85 %
Entera Bio Ltd   20.82 %
United Therapeutics Corporation  20.18 %
Ligand Pharmaceuticals Incorporated  20.06 %
Harmony Biosciences Holdings inc   20.06 %
Pediatrix Medical Group Inc   19.89 %
Theravance Biopharma inc   19.40 %
Krystal Biotech Inc   19.34 %
Ani Pharmaceuticals Inc  19.33 %
Brightspring Health Services Inc   18.93 %
Sbc Medical Group Holdings Incorporated  18.69 %
West Pharmaceutical Services Inc   18.51 %
Intuitive Surgical Inc   17.82 %
Standard Biotools Inc   17.64 %
Inspire Medical Systems inc   17.62 %
Medinotec Inc   17.47 %
Lemaitre Vascular Inc   16.93 %
Ufp Technologies Inc   16.72 %
Ensign Group Inc  16.53 %

Date modified: 2026-08-12T20:54:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.